Insider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells 51,110 Shares of Stock

Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella sold 51,110 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $26.27, for a total transaction of $1,342,659.70. Following the completion of the sale, the president now directly owns 160,260 shares of the company’s stock, valued at $4,210,030.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Beam Therapeutics Stock Up 1.3 %

Shares of NASDAQ:BEAM traded up $0.35 during midday trading on Wednesday, reaching $26.69. 1,466,604 shares of the company were exchanged, compared to its average volume of 1,231,249. The firm has a market cap of $2.20 billion, a PE ratio of -14.80 and a beta of 1.85. Beam Therapeutics Inc. has a fifty-two week low of $16.95 and a fifty-two week high of $49.50. The stock has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $25.09.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02. The company had revenue of $11.80 million for the quarter, compared to analysts’ expectations of $14.18 million. Beam Therapeutics had a negative net margin of 40.56% and a negative return on equity of 16.22%. Beam Therapeutics’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.08) EPS. As a group, analysts forecast that Beam Therapeutics Inc. will post -4.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Beam Therapeutics by 5.1% in the 4th quarter. Vanguard Group Inc. now owns 7,164,876 shares of the company’s stock worth $195,028,000 after purchasing an additional 349,906 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Beam Therapeutics by 144.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,564 shares of the company’s stock valued at $43,000 after purchasing an additional 923 shares during the period. Riverview Trust Co purchased a new position in Beam Therapeutics during the 1st quarter valued at about $26,000. DLK Investment Management LLC bought a new stake in Beam Therapeutics during the first quarter valued at approximately $239,000. Finally, Thrive Wealth Management LLC purchased a new position in Beam Therapeutics in the 1st quarter worth $229,000. Institutional investors and hedge funds own 99.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on BEAM. Scotiabank started coverage on shares of Beam Therapeutics in a research report on Wednesday. They set a “sector outperform” rating and a $24.00 target price on the stock. Stifel Nicolaus raised their target price on shares of Beam Therapeutics from $66.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research note on Thursday, August 22nd. JPMorgan Chase & Co. boosted their price target on Beam Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a report on Tuesday, August 6th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.50.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.